UNSPSC 51411603: Buphenine or nylidrin

This classification denotes a beta-adrenergic agonist with the molecular formula C19H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 695DKH33EI, chemically known as benzyl alcohol, p-hydroxy-alpha-(1-((1-methyl-3-phenylpropyl)amino)ethyl)- but generally known as buphenine, which bears US NIH Compound Identifier 4567. Buphenine most often comes in base and hydrochloride forms. European Medicines Agency schedules Buphenine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05981MIG.

UNSPSC 51411603 Buphenine or nylidrin (Commodity) covers advanced life support and emergency medications supplied to state and local emergency response agencies, health departments, and cooperative purchasing alliances for distribution through authorized wholesalers and direct procurement. State and local buyers—primarily fire rescue departments, health and human services commissions, and multistate cooperative purchasing organizations—source these medications through sealed competitive bids, requests for information, and master agreement solicitations that establish pricing, supply chain compliance, and product specifications for recurring delivery. The work involves manufacturing and wholesale distribution of generic and brand-name pharmaceuticals meeting FDA and Drug Supply Chain Security Act requirements, with vendors warranting product quality, managing expiration cycles, and arranging just-in-time or scheduled delivery to emergency and health system endpoints.

The City of Tampa's Purchasing Department solicited advanced life support medications including Epinephrine, Labetalol, Adenosine, and Diltiazem for Tampa Fire Rescue on a sealed-bid basis (IFB No. 26P00188, due April 8, 2026) with an estimated contract value of $40,000 and a one-year term plus renewal options; the Texas Health and Human Services Commission issued an RFI (HHS0017013, due April 3, 2026) on direct-to-manufacturer prescription fulfillment models; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with awards effective July 1, 2026. Recent activity spans Florida, Texas, and the upper Midwest, with solicitations emphasizing cGMP certification, DSCSA compliance, comprehensive product data (NDC codes, SKUs, UPCs), expiration-date warranties of nine months to one year minimum shelf life, and electronic ordering through procurement portals or ePro systems.